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ABSTRACT 
The aim of this study was to evaluate the effect of zoledronic acid (ZA) and denosumab on low 
back pain (LBP) and Modic change (MC) over 6 months. Adults aged ≥40 years with 
significant LBP for at least 6 months duration and MC (type 1, 2 or mixed) were randomised 
to receive ZA (5mg/100ml), denosumab (60mg), or placebo. LBP was measured monthly by 
Visual Analogue Scale (VAS) and the LBP Rating Scale (RS). MC was measured from MRIs 
of T12-S1 vertebrae at screening and 6 months. 103 participants with moderate/severe LBP 
(mean VAS=57mm, mean RS=18) and median total MC area 538 mm2, were enrolled. 
Compared to placebo, LBP reduced significantly at 6 months in the ZA group for RS (-3.3, 95% 
CI -5.9 to -0.7) but not VAS (-8.2, 95% CI -18.8 to +2.4) with similar findings for denosumab 
(RS -3.0, 95% CI -5.7 to -0.3, VAS -10.7, 95% CI -21.7 to +0.2). There was little change in 
areal MC size overall and no difference between groups with the exception of denosumab in 
those with type 1 Modic change (-22.1mm2, 95% CI -41.5 to -2.7). In post-hoc analyses, both 
medications significantly reduced VAS LBP in participants with milder disc degeneration and 
non-neuropathic pain, and denosumab reduced VAS LBP in those with type 1 MC over 6 
months, compared to placebo. Adverse events were more frequent in the ZA group. These 
results suggests a potential therapeutic role for ZA and denosumab in MC-associated LBP. This 
article is protected by copyright. All rights reserved  
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INTRODUCTION 
Chronic low back pain (LBP) is a common and disabling problem, for which there are few 
treatment options.(1) While no specific pathologies are present in the majority of people with 
LBP (>85%),(2) a subset of patients have one type of pathology, Modic changes (MC), which 
is strongly associated with non-specific LBP.(3) MC is an independent risk factor for LBP,(4 5) 
suggesting it is an independent source of pain and a treatment target for LBP.  
Modic et al.(6 7) described three types of vertebral endplate bone abnormalities (MC) which are 
visualised on MRI. Type 1 MC is proposed as the initial stage, indicating inflammation and 
oedema; type 2 and 3 MC are considered stable stages and represent fatty degeneration and 
bone sclerosis, respectively. Previous population-based research reported that type 1 MC is 
more likely to be associated with LBP and poor prognosis than other MC types.(8-10) Types of 
MC can transform from one type to another, and the distinction between different types of MC 
are complex,(11-13) but transformation of type 1 MC to type 2 correlates with improvement in 
symptoms.(14)  
A few clinical trials have been performed in MC-associated LBP. An uncontrolled trial of rest 
versus exercise showed similar and small effects on LBP over one year.(15) Intra-discal 
glucocorticoid injection reduced LBP intensity at 1 month but pain rebounded quickly.(16) Oral 
antibiotics significantly improved LBP symptoms and decreased MC size.(17) However, a 
recent study failed to replicate these results,(18) and side effects may limit usage. Intravenous 
bisphosphonates, such as zoledronic acid (ZA) and pamidronate, have shown analgesic effects 
on LBP.(19-21) Moreover, in a small study ZA had a short-term effect on pain in patients with 
LBP and MC, but no MRI endpoints were reported.(21) ZA is effective for knee osteoarthritis 
related bone marrow lesions (BMLs),(22) which have similar characteristics and MRI 
appearance to MC,(23) suggesting similar pathology. An observational study reported that 
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denosumab, a fully human monoclonal antibody, was effective in the treatment of bone marrow 
oedema with lower extremity pain,(24) but there are no studies in LBP. Therefore, the aim of 
this proof of principle study was to assess the effect of ZA (5mg) and denosumab (60mg) on 
LBP symptoms and MRI-detected MC, in participants with LBP and type 1, 2 or mixed MC. 
 
METHODS 
Trial design 
This study is a single-centre, double-blind, placebo-controlled, randomised parallel-group trial 
of a single dose of either intravenous ZA (5mg) or subcutaneous denosumab (60mg) versus 
placebo with a 1:1:1 allocation ratio. 
 
Setting and participants 
Participants were recruited from August 2014 to October 2015 from the back pain clinic of the 
Royal Hobart Hospital and through local advertising. Participants aged ≥40 years with 
significant LBP (≥40 on a 100mm visual analogue scale (VAS)) for at least 6 months, and at 
least one endplate from T12-S1 with MC (type 1, 2 or mixed) were eligible for inclusion. 
Exclusion criteria are detailed in Supplementary Table 1. Potential participants then had a 
screening MRI, and those with no MC or with only type 3 MC were excluded. Regular use of 
other medication was allowed except for high dose opiates.  
Informed consent was obtained from all participants, and ethics approval for the study was 
granted by the Tasmanian Human Research Ethics Committee. This study was registered with 
the Australian New Zealand Clinical Trials Registry (ACTRN12614000719639). 
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Randomisation and interventions 
Participants were randomised to receive one of three treatments: zoledronic acid 5mg/100ml, 
denosumab 60mg/1ml, placebo (saline 100ml/1ml) using a double dummy approach. 
Participants were randomised into one of three study arms based on computer-generating 
random numbers using adaptive allocation, stratified by type 1 MC (with or without). This was 
conducted by a staff member with no direct involvement in the study. The allocated treatment 
was dispensed by one author (LLL) and administered by a nurse who was unblinded, neither 
of whom assessed any study outcomes. All participants and assessors were blinded to treatment 
allocation throughout the trial. 
 
Outcomes 
Chief outcomes were changes in LBP assessed using VAS (0-100mm), and total MC size (mm2) 
on MRI over 6 months. 
Other outcomes were changes in LBP (the Low Back Pain Rating Scale (RS)),(25) disability 
(the Roland-Morris Disability Questionnaire (RMDQ)),(26) utility (calculated using the 
Assessment of Quality of Life (AQoL) questionnaire)(27), response to therapy (based on the 
Osteoarthritis Research Society International (OARSI) responder criteria for clinical trials)(28) 
after 3 and 6 months, and change in the proportion of participants with type 1 MC after 6 
months. Safety outcomes included acute phase reactions(29) and any adverse events over 6 
months. Blinding was assessed after 6 months to determine whether participants correctly 
guessed which treatment arm they were allocated to. 
Participants who withdrew from the study before 6 months were invited to have a second MRI 
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scan at the sixth month. 
 
Pain and disability 
LBP was assessed using a 100mm VAS from 0 (none) to 100 (unbearable) by asking “Thinking 
about your low back, where would you rate your pain? Use the last seven days as a time frame”.  
The pain subscale of the RS (score range 0-30) was also used to assess LBP, combining three 
sub-questions rated from (0 (no pain) to 10 (worst pain imaginable)) for current pain intensity 
and the worst (0-10) and average pain (0-10) in the past two weeks.(25) RMDQ (0-24 scores) 
was used to evaluate disability due to back pain with 24 indicating the worst.(26) LBP (VAS 
and RS) and disability scores were recorded at baseline and then monthly. Clinically significant 
improvements were defined as a 15mm reduction in VAS and 5 in RMDQ.(30) 
 
MRI assessment 
MRI scans were performed at screening and 6 months with a 1.5T non-contrast scan (GE 
Optima 450W, Milwaukee, USA). The imaging sequences were sagittal T1-weighted and fat-
saturated T2-weighted Fast Spin Echo (FSE), and T2-weighted Fast Recovery Fast Spin Echo 
(FRFSE) (T1 FSE: repetition time 489ms, echo time 10ms; fat-saturated T2 FSE: repetition 
time 3490ms, echo time 102ms; T2 FRFSE: repetition time 3206ms, echo time 102ms). Other 
technical specifications included a slice thickness of 4mm with spacing 0.5mm, matrix 
416×224 and a field of view 32cm.  
Presence and location of MC at screening was assessed by a radiologist (AH) for the purposes 
of patient enrolment. Scoring of MC was performed by a trained observer (GC), blinded to 
treatment allocation using OsiriX software (University of Geneva, Geneva, Switzerland). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved 
Screening and 6 months scans were read paired with the chronological order known to the 
reader. The endplates were measured from the upper endplate of T12 down to the upper 
endplate of S1, which is the field of view of the MR images. The maximum area (mm2) of MC 
at each endplate was measured (excepting endplates with type 3 MC), and these were summed 
to create total MC size at screening and 6 months (Figure 1). The type of MC at each vertebral 
endplate was determined according to previous descriptions.(11) Disc degeneration of each 
intervertebral disc at screening was measured using the Pfirrmann Grading System (level 1-
5),(31) where 5 was considered severe, and the maximum level of disc degeneration for each 
participant was recorded. There was excellent intra-observer repeatability for disc degeneration, 
MC size and MC type, with intraclass correlation coefficients from 0.93 to 0.99.  
 
Responder criteria 
The OARSI responder criteria combines improvements of pain, function and patient’s global 
assessment to create a treatment effect which is based on osteoarthritis clinical trials.(28) We 
adapted this approach for use in LBP, combining patient’s global assessments, LBP VAS for 
pain and RMDQ scores for function to generate a treatment responder variable (0: no responder; 
1: responder). Patient’s global assessments were assessed using a 100mm VAS, with 0 
indicating very well and 100 very poorly. 
 
Other measures 
Utility scores (0-1) were calculated based on the 4-dimension AQoL questionnaire, with 0 
indicating the worst health state and 1 the best.(27) Neuropathic pain was assessed by the 
painDETECT questionnaire (-1 to 38) at screening. A painDETECT score <12 was defined as 
unlikely neuropathic pain, and 13-18 as possible neuropathic pain.(32) Depression (as assessed 
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using the Patient Health Questionnaire (PHQ-9) (0-9))(33) and use of concomitant medications 
at baseline were recorded to address their potential effects on pain. Blinding was assessed by 
asking participants “What treatment do you think you received” with offering the following 
options: “Zoledronic acid” or “Denosumab” or “Placebo” or “Either active treatment” or “Not 
sure”.   
 
Sample size 
This study was a proof of principle study, and therefore no formal sample size calculation was 
performed.(34) In consideration of the similarity between MC and BMLs, we based the sample 
size on our previous study of ZA in knee osteoarthritis,(22) in which we were able to demonstrate 
a statistically significant difference in knee pain and BML size with a sample size of n=30 per 
group. Thus, we planned to recruit at least 90 participants in this study. 
 
Statistical analysis  
All analyses followed an intention-to-treat principle. Changes in LBP, size of MC, proportion 
of participants with type 1 MC, disability and utility scores were analysed using mixed-effect 
modelling and generalised estimating equations. In mixed-effect modelling, fixed effects were 
month, treatment group and their interaction; random intercept was participant identification. 
Missing values (6%-13% missing) on these six repeated measure outcomes were addressed 
using maximum-likelihood estimation (mixed-effect modelling and generalised estimating 
equations).(35) The adjustments for clinically important covariates at baseline (age, gender, 
depression, type 1 MC, size of MC, duration of symptoms and/or concomitant medication) 
made no meaningful change to the model coefficients, so we did not include any of them in the 
final models. 
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Treatment responders were regressed on treatment allocation using log binomial models 
separately at 3 and 6 months. Multiple imputations by chained equations were used to address 
missing values on treatment responders (10%-14% missing). Twenty imputations were 
performed using baseline variables with complete data assuming missing at random (age, 
gender, BMI, concomitant medication, type 1 MC and treatment allocation).  
Post-hoc analyses were performed to identify subgroups in which these treatments may be more 
effective. For change in VAS LBP and disability we examined potential interactions between 
treatment effects (treatment over time) and severity of disc degeneration (severe/milder), 
presence or absence of type 1 MC and size of MC (above/below the median size) at screening. 
Given the exploratory nature of this study, interactions were only evaluated as whether they 
were potentially clinically important rather than by statistical significance. If the effect size of 
an interaction item was clinically significant, stratified analysis was performed. A pre-specified 
sensitivity analysis was used to determine whether the change in LBP (VAS and RS) was 
influenced by persons in whom the presence of neuropathic pain was uncertain (painDETECT 
score 12-19).(32) Additionally, we performed a subgroup analysis for the change of MC size in 
endplates with only type 1 MC at screening. Time-course analysis was used to explore the 
trajectory of treatment effects on LBP and disability. Analyses were performed using Stata 
version 14.2 (Stata Corporation). A two-sided p-value of 0.05 was considered statistically 
significant. 
 
RESULTS 
Participants 
A total of 171 participants were screened and 103 participants randomised to receive either ZA 
(n=35), denosumab (n=31), or placebo (n=37). Six participants (6%) withdrew from the study 
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during the 6 months follow-up. Ninety-five (92%) participants completed questionnaires and 
96 (93%) had MRIs at 6 months. Figure 2 shows the trial flowchart.  
At baseline, participants were older adults (mean age 59.8±10.1), who were predominantly 
males (39% females) with moderate to severe LBP (mean VAS of 57mm) and MC visible at 1 
or more lumbar vertebrae (median size of 538 mm2). The three groups were generally well 
matched on baseline characteristics except for sex and MC size (Table 1).  
 
Chief outcomes 
The chief outcomes are presented in Table 2. Compared to baseline, VAS LBP reduced in all 
three groups over 6 months. There were no statistically significant differences in the reductions 
of VAS LBP between either the ZA or the denosumab group and placebo, though the 10.7 mm 
greater reduction in the denosumab group compared to placebo approached statistical 
significance (p=0.06). The size of all MC changed little in any group and there were no 
significant between group differences.  
 
Other outcomes 
Other outcomes are shown in Table 2. Compared to placebo, both ZA and denosumab 
significantly improved LBP (as assessed by the RS) after 6 months; ZA also decreased RS and 
disability scores after 3 months. There was no change in the proportion of participants with 
type 1 MC or in utility scores in either treatment group, compared to placebo. Proportions of 
responders at 3 and 6 months were higher in the ZA and denosumab group than that in the 
placebo group, but these differences were not statistically significant. For assessment of 
blinding, 30% participants in the ZA group, 10% in the denosumab group and 18% in the 
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placebo group correctly guessed what they had been allocated to (Supplementary table 2). 
 
Post-hoc analyses 
Post-hoc analyses are also presented in Table 2. Effect sizes of interactions with both severity 
of disc degeneration and presence or absence of type 1 MC for VAS LBP reached clinical 
significance. In stratified analyses, both ZA and denosumab significantly improved LBP in 
persons with milder disc degeneration over 6 months, and denosumab improved LBP in those 
with type 1 MC, compared to placebo. Subgroup analysis showed that the size of type 1 MC 
was increased in the ZA and the placebo groups, but was slightly decreased in the denosumab 
group and this difference was statistically significant when compared to placebo. Sensitivity 
analysis found both treatments significantly improved LBP (VAS and RS) compared to placebo 
in participants without neuropathic pain.  
Time-course analysis showed that LBP and disability scores in the ZA group decreased 
significantly after one month and remained relatively stable over the remaining 5 months 
(Figure 3). The effect of denosumab on LBP peaked at 2 months with little change between 2 
and 6 months. 
 
Adverse events 
Adverse events were common, with all 35 participants (100%) in the ZA group, 27 (87%) in 
the denosumab group and 25 (68%) in the placebo group reporting at least one adverse event 
over 6 months (Table 3). Most of the adverse events were acute phase reactions in the ZA 
group: primarily flu-like symptoms, headache-dizzy, musculoskeletal pain and stiffness, and 
psychological effects (eg. malaise, insomnia and depression). Three participants experienced 
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one serious adverse event (non-elective hospital admission): from the placebo group one 
participant had a food allergy and another severe vomiting and dehydration while traveling; 
one participant from the ZA group fell after taking diazepam. Two participants from the 
placebo group withdrew due to adverse events. 
 
 
DISCUSSION 
In this proof of principle study, one-off treatment with either infusion of ZA (5mg/100ml) or 
subcutaneous injection of denosumab (60mg/1ml) were effective for the treatment of MC-
associated LBP assessed by LBP RS but not VAS, but did not significantly change overall areal 
MC size over 6 months. Furthermore, post-hoc analyses suggested both therapies had 
significant benefit for LBP in patients with specific MRI characteristics (milder disc 
degeneration or type 1 MC) and non-neuropathic pain. These pilot findings imply these 
therapies will work better in persons with earlier disease with non-neuropathic pain. 
There were differences in the effects of ZA and denosumab compared to placebo on pain 
depending on the method of pain assessment used. There were no statistically significant 
between-group differences in LBP assessed by VAS, though there was a trend to a statistically 
significant reduction for the denosumab group compared to the placebo group (p=0.06), 
although the magnitude (10.7mm) was not clinically important. In contrast, improvements in 
LBP as assessed by the RS were statistical significant in both active treatment groups over 6 
months, compared to placebo. This discrepancy may be due to the different time anchors (VAS 
pain – last 7 days vs. RS – last two weeks plus the present), or slight differences in wording. 
Also, while RS specifies 3 questions for the worst, average and current pain, VAS in this study 
recorded the average LBP only. These differences may make RS more sensitive than VAS for 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved 
LBP assessment.  
The effects on pain from ZA occurred early in the treatment period (1 month) for both LBP 
and disability. This was similar to a previous trial where ZA significantly reduced LBP (using 
a 10cm VAS) after 1 month but not after 12 months.(21) ZA predominantly showed a long but 
not short term effect on LBP in this trial, but the pain curves did separate at 1 month. This 
result was unexpected but is consistent with the very rapid effect of ZA on bone turnover 
markers in osteoporosis (36) and Paget’s disease.(37) Maximal effects on LBP were observed 
after 2 months in the denosumab-treated patients. The effect of denosumab on bone resorption 
wears off quickly from around the five month mark. We expected this would correlate with 
change in pain but did not observe any worsening of pain before the end of the trial. A longer 
duration of follow up would be required to explore this further.  
The analgesic effects of ZA and denosumab on MC-associated LBP may be due to their role 
in osteoclast inhibition(38 39) or inflammation.(40) Elevated levels of osteoclast activators have 
been detected in intervertebral discs with adjacent MC compared to those without,(41) meaning 
osteoclasts may be involved in the pathogenesis of MC. In animal experiments, osteoclastic 
bone resorption has been associated with inflammatory skeletal pain,(42) which can be improved 
by the administration of bone-active agents.(43 44) Biomechanical theory suggests that traumatic 
inflammation in the endplates may be a source of MC-associated LBP.(6 45) Upregulation of 
pro-inflammatory cytokines has been found in endplates with MC,(46-48) and localised anti-
inflammatory therapy has shown a short-term effect on MC-associated LBP.(16) Hence, the anti-
inflammatory effect of ZA may also contribute to relieving LBP associated with MC. 
In post-hoc analysis, both therapies were more effective on LBP in persons with milder disc 
degeneration than with severe disc degeneration, suggesting they may work better earlier in the 
disease course. Previous research has been inconclusive about whether the size or type of MC 
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is associated with LBP symptoms.(8 9 49) We observed that denosumab reduced VAS LBP more 
in persons with type 1 MC. Both medications statistically significantly relieved LBP in persons 
without neuropathic pain, which would be expected given their mechanism of action.  
There was little change in MC size (<10mm2 or 1% of baseline size) in any treatment group 
over the course of the trial. This is in contrast to our previous study, where ZA reduced knee 
osteoarthritis related BML area by 164mm2 (35% of baseline size) compared to placebo over 
6 months.(22) MC pathology may be different to BML pathology and may take longer to respond 
to treatment with bone-active agents. Our study may not have been long enough to observe an 
effect. Similarly, in a small randomised controlled trial, Koivisto et al found that ZA did not 
significantly reduce the size of MC over one year, but ZA accelerated the conversion of type 
1-dominant to type 2-dominant MC.(50) The progression of LBP symptoms and MC may be at 
least partially independent of each other and this is a potential reason why the treatments in our 
trial improved LBP symptoms but did not significantly change MC size or type. However, we 
found that denosumab prevented an increase in type 1 MC size, but the change was small in 
magnitude.   
As expected, adverse events were more frequent in the ZA group than that in the placebo group. 
The major adverse events in the ZA group were similar to those previously described,(29) and 
no new safety signals were identified. 
Strengths of this study include the high follow-up (94%) over 6 months, areal measurements 
for MC and detailed records of clinical symptoms at each month of follow-up. The study also 
has limitations. Firstly, this was a proof of principle study, in which the sample size was modest, 
so this study should be regarded as hypothesis generating for subsequent trials. Secondly, the 
follow-up may not have been long enough to detect a structural change, and a recent study 
suggested that one year follow-up may be required.(50) Therefore, we cannot be sure of whether 
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the treatment effect on LBP was related to the changes in MC size or type, or to other MC 
characteristics that were not measured. Thirdly, the frequency of acute phase reactions in ZA-
treated group was higher than in other two groups, this might weaken the strength of blinding. 
However, patient-reported assessment of treatment blinding demonstrated that only 30% of 
patients in the ZA group correctly guessed that they were given ZA; this is no better than chance 
and suggests that blinding has been successful. Finally, results from post hoc analyses were 
exploratory and should be confirmed further. 
In conclusion, both ZA and denosumab may reduce LBP but do not change overall MC area 
over 6 months, but denosumab may reduce type 1 MC size. This study suggests a potential 
therapeutic role for ZA and denosumab in MC-associated LBP.  
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Figure Legends  
 
Figure 1. Measurement of the total area of Modic changes. The maximum size of Modic 
changes was measured for each participant at each endplate. In this example, the 
maximum size of Modic changes at each endplate was recorded (lower endplates of L4 
(A) and L5 (C), and upper endplates of L5 (B) and S1 (D)), and the total area of Modic 
changes for this participant was the sum of the maximum area of Modic changes at these 
four endplates. 
 
 
Figure 2. Study flow diagram. *Missed appointments are defined as no questionnaire 
available at the follow-up 
 
 
Figure 3. The changes of LBP (VAS and RS) and disability (RMDQ) among different 
treatments (placebo) over 6-month follow-up, p-values indicate the individual between-
group changes (active vs placebo) at 6 months. 
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Table 1. Baseline Characteristics of study participants, by treatment received † 
  Zoledronic Acid Denosumab Placebo (N = 35) (N = 31) (N = 37) 
Age, years 57.7 (8.5) 60.0 (11.0) 61.5 (10.5) 
Female, n (%) 11 (31) 16 (52) 13 (35) 
BMI ‡, kg/m2 29.2 (5.6) 29.8 (5.3) 29.8 (5.4) 
Duration of LBP, years, median (IQR) 25 (4-30) 20 (5-30) 10 (5-20) 
Size of MC, mm2, median (IQR)   697 (273-1155)      532 (255-893)     389 (164-780) 
Types of MC *, n (%)    
     Any type 1 MC   9 (26) 11 (35) 9 (24) 
     Any type 2 MC 24 (69) 23 (74) 26 (70) 
     Any mixed-type MC  32 (91) 30 (97) 33 (89) 
LBP VAS, 0-100 59.5 (15.5) 55.3 (16.8) 56.3 (21.8) 
LBP RS, 0-30 18.7 (4.4) 17.3 (4.6) 16.8 (5.7) 
RMDQ, 0-24 11.5 (4.5) 10.5 (4.8) 11.1 (5.3) 
Utility, 0-1 0.56 (0.23) 0.61 (0.17) 0.60 (0.22) 
PHQ-9, 0-27, median (IQR)   6 (3-10) 5 (1-6) 4 (2-8) 
Disc degeneration, (%)    
     Severe (level 5) 17 (49) 15 (48) 15 (41) 
     Milder (level 2-4) $ 18 (51) 16 (52) 22 (59) 
PainDetect, n (%)    
     Uncertain neuropathic pain   1 (3) 4 (13) 1 (3) 
     Non-neuropathic pain 34 (97) 27 (87) 36 (97) 
Medication use £, n (%)    
     Cox-2 inhibitor   4 (11) 1 (3) 2 (5) 
     Fish oil   8 (23) 7 (23) 7 (20) 
     Glucosamine   4 (11) 4 (13) 3 (8) 
     NSAIDs 13 (37) 10 (32) 16 (43) 
     Paracetamol 19 (54) 21 (68) 21 (57) 
     Number of analgesics   1 (1-2) 1 (1-2) 1 (1-2) 
Abbreviations: BMI, body mass index; IQR: interquartile range; LBP, low back pain; MRI, 
magnetic resonance imaging; NSAIDs, non-steroid anti-inflammatory drugs; PHQ-9, patient 
health questionnaire; RMDQ, Roland-Morris disability questionnaire; RS, rating scale; VAS, 
visual analogue scale. 
† Values of this table were presented as mean (SD) unless otherwise specified (n (%) or median 
(IQR)); 
‡ BMI were calculated as weight in kilograms divided by height in meters squared; 
* One participant might have different types of MC at different endplates; 
$ All participants have at least level 2 disc degeneration (using the Pfirrmann Grading System); 
£ Participants may use more than one type of these medications. 
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       Table 2. Change in study outcomes between active treatments (ZA or denosumab) and placebo over 3 and 6 months † 
 Mean change from baseline (95%CI) Zoledronic Acid vs. Placebo Denosumab vs. Placebo 
 Zoledronic Acid Denosumab Placebo Absolute Difference Relative Risk Absolute Difference Relative Risk 
  (N = 35) (N =31) (N=37) Mean (95% CI) (95% CI) Mean (95% CI) (95% CI) 
Chief outcomes (6 months)          
  LBP VAS, 0-100  -21.5 (-29.1 to -13.9) -24.0 (-32.1 to -16.0) -13.3 (-20.8 to -5.8) -8.2 (-18.8 to 2.4) - -10.7 (-21.7 to 0.2) - 
  Size of MC, mm2  -1.1 (-16.8 to  14.7) -4.1 (-20.7 to  12.4) -3.9 (-19.6 to 11.9) 2.8 (-19.5 to 25.1) - -0.3 (-23.1 to 22.6) - 
Other outcomes         
3 Months         
  LBP RS, 0-30  -5.4 (-7.3 to -3.5) -4.3 (-6.3 to -2.2) -1.9 (-3.9 to 0) -3.5 (-6.2 to -0.8) - -2.3 (-5.1 to 0.5) - 
  RMDQ, 0-24  -3.5 (-4.9 to -2.2) -1.2 (-2.6 to 0.2) -1.4 (-2.8 to -0.1) -2.1 (-4.0 to -0.2) - 0.3 (-1.7 to 2.2) - 
  Utility, 0-1  0.03 (-0.02 to 0.08) 0.01 (-0.04 to 0.07) 0.02 (-0.03 to 0.07) 0.01 (-0.06 to 0.08) - -0.01 (-0.08 to 0.06) - 
  Responders ‡, n/N (%) 19/32 (59.4) 13/28 (46.4) 12/29 (41.4) 18.0 (-7.7 to 43.6)  1.4 (0.8 to 2.4) 5.0 (-21.7 to 31.8) 1.1 (0.6 to 2.0) 
6 Months         
  LBP RS, 0-30  -6.3 (-8.2 to -4.4) -6.0 (-8.0 to -4.0) -3.0 (-4.9 to -1.1) -3.3 (-5.9 to -0.7) - -3.0 (-5.7 to -0.3) - 
  RMDQ, 0-24  -3.2 (-4.5 to -1.9) -1.6 (-3.0 to -0.2) -1.8 (-3.1 to -0.5) -1.4 (-3.2 to 0.5) - 0.2 (-1.7 to 2.1) - 
  Utility, 0-1  0.09 (0.04 to 0.13) 0.02 (-0.03 to 0.08) 0.05 (0 to 0.10) 0.03 (-0.04 to 0.10) - -0.03 (-0.10 to 0.04) - 
  Type 1 MC *, (%)  0.4 (-10.3 to 11.1) -16.2 (-27.7 to -4.7) -10.3 (-20.0 to -1.0) 10.7 (-3.7 to 25.0) 1.8 (0.9 to 3.6) -5.9 (-20.9 to 9.2) 0.9 (0.4 to 2.0) 
  Responders ‡, n/N (%) 22/33 (66.7) 16/29 (55.2) 15/31 (48.4) 18.3 (-6.4 to 42.9) 1.3 (0.8 to 2.0) 6.8 (-19.4 to 33.0) 1.1 (0.7 to 1.7) 
Post-hoc outcomes (LBP VAS over 6 months)       
  Severe disc degeneration 
 
 -17.0 (-28.0 to -6.0) -21.7 (-33.1 to -10.3) -18.8 (-30.8 to -6.8) 1.8 (-14.5 to 18.0) - -2.9 (-19.4 to 13.7) - 
  Milder disc degeneration 1  -25.1 (-35.2 to -14.9) -26.3 (-37.3 to -15.3) -10.3 (-19.7 to -1.0) -14.7 (-28.5 to -0.9) - -16.0 (-30.4 to -1.5) - 
  With type 1 MC 2 
 
 -22.6 (-36.9 to -8.2) -35.6 (-48.6 to -22.6) -13.0 (-29.6 to 3.6) -9.6 (-31.5 to 12.4) - -22.7 (-43.8 to -1.6) - 
  Without type 1 MC  -21.1 (-29.8 to -12.4) -17.2 (-27.2 to -7.3) -13.3 (-21.5 to -5.1) -7.8 (-19.8 to 4.2) - -3.9 (-16.9 to 9.0) - 
Participants with non-neuropathic pain 3       
  LBP VAS, 0-100  -23.0 (-30.6 to -15.3) -25.8 (-34.4 to -17.2) -12.2 (-19.8 to -4.7) -10.8 (-21.5 to 0.0) - -13.6 (-25.0 to -2.1) - 
  LBP RS, 0-30   -6.5 (-8.4 to -4.6) -6.3 (-8.5 to -4.2) -2.7 (-4.6 to -0.9) -3.8 (-6.5 to -1.1) - -3.6 (-6.4 to -0.8) - 
Subgroup analysis         
  Size of Type 1 MC, mm2 17.9 (4.5 to 31.3) -4.6 (-16.7 to 7.5) 17.5 (2.3 to 32.7) 0.4 (-19.8 to 20.7) - -22.1 (-41.5 to -2.7) - 
Abbreviations: CI: confidence interval; LBP, low back pain; RMDQ, Roland-Morris disability questionnaire; RS, rating scale; VAS, visual analogue scale.  
† Changes from baseline to 3 and 6 months among the three groups were compared using mixed-effects linear regression, unless otherwise specified; 
‡ Responder were evaluated using the OARSI responder criteria. The number and proportion of responders in each group were displayed at 3 and 6 months; absolute difference and relative risk (RR) were calculated by 
treatment group minus placebo group using log binomial regression after multiple imputation for missing values; 
* Absolute difference and relative risk (RR) in the proportion of participants with type 1 MC were calculated by treatment group minus placebo group using generalised estimating equations;  
1 Sample size in milder disc degeneration subgroups: n=18 in the ZA group, n=16 in the denosumab group and n=22 in the placebo group; 
2 Sample size in type 1 MC subgroups: n=9 in the ZA group, n=11 in the denosumab group and n=9 in the placebo group; 
3 Sample size in non-neuropathic pain (painDETECT score of <12) subgroups: n=34 in the ZA group, n=27 in the denosumab group and n=36 in the placebo group; 
Bolder numbers indicate statistical significance (p<0.05).
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Table 3. Adverse events † 
 Zoledronic Acid Denosumab Placebo 
(N = 35) (N = 31) (N = 37) 
Participants with at least one adverse event 35 (100) 27 (87) 25 (68) 
Acute Phase Reactions ‡, n 85 33 26 
     Constipation 0 (0) 0 (0) 1 (3) 
     Diarrhoea 3 (9) 0 (0) 1 (3) 
     Flu-like 22 (63) 5 (16) 7 (19) 
     Headache-dizzy 20 (57) 10 (32) 8 (22) 
     Musculoskeletal pain and stiffness 18 (51) 8 (25) 2 (5) 
     Psychological effects * 21 (60) 10 (32) 7 (19) 
     Rash 1 (3) 0 (0) 0 (0) 
Other adverse events ‡, n 10 13 18 
     Conjunctivitis 0 (0) 1 (3) 0 (0) 
     Flu-like 0 (0) 1 (3) 1 (3) 
     Headache-dizzy 0 (0) 0 (0) 2 (5) 
     Musculoskeletal pain and stiffness 7 (20) 9 (29) 12 (32) 
     Psychological effects * 2 (6) 2 (6) 3 (8) 
     Pneumonia 1 (3) 0 (0) 0 (0) 
Elective surgery (other than back problem) 2 (6) 2 (6) 2 (5) 
Serious adverse events    
     Non-elective hospital admission 1 (3) 0 (0) 2 (5) 
† Values of this table are presented as n (%) unless otherwise specified (n); 
‡ Some participants may experience more than one adverse event; acute phase indicates 
within 3 days post therapy; 
* Psychological effects in this study mainly included malaise, insomnia and depression.
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